Syndax reports Q4 EPS ($1.00), consensus (99c)

As of December 31, 2023, Syndax had cash, cash equivalents, and short and long-term investments of $600.5M and 85.1M common shares and prefunded warrants outstanding. “2023 was a landmark year for Syndax marked by execution across all of our major clinical, regulatory, and operational milestones,” said Michael A. Metzger, CEO. “With the axatilimab BLA filing under FDA Priority Review and receipt of a PDUFA action date for revumenib anticipated later this quarter, preparations are well underway for the potential launch of both first- and best-in-class drugs later this year. We are committed to maximizing the full potential of these therapies beyond their initial approvals through expansion into earlier lines of therapy in combination with standard of care agents and into new indications. With a strong cash position that is expected to fund operations through 2026, Syndax is well positioned for continued success and long-term growth.”